Zymeworks BC Inc [ZYME] stock is trading at $24.02, up 0.84%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ZYME shares have gain 29.70% over the last week, with a monthly amount glided 37.97%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on October 14, 2025, and kept the price target unchanged to $26. On October 10, 2025, B. Riley Securities initiated with a Buy rating and assigned a price target of $30 on the stock. TD Cowen started tracking the stock assigning a Buy rating. JP Morgan upgraded its rating to an Overweight but $18 remained the price target by the analyst firm on December 16, 2024. Leerink Partners upgraded its rating to Outperform for this stock on November 07, 2024, and upped its price target to $25. In a note dated November 01, 2024, Wells Fargo downgraded an Equal Weight rating on this stock but restated the target price of $12.
Zymeworks BC Inc [ZYME] stock has fluctuated between $9.03 and $26.19 over the past year. Currently, Wall Street analysts expect the stock to reach $32 within the next 12 months. Zymeworks BC Inc [NASDAQ: ZYME] shares were valued at $24.02 at the most recent close of the market. An investor can expect a potential return of 33.22% based on the average ZYME price forecast.
Analyzing the ZYME fundamentals
Zymeworks BC Inc [NASDAQ:ZYME] reported sales of 134.48M for the trailing twelve months, which represents a growth of 72.59%. Gross Profit Margin for this corporation currently stands at 0.97% with Operating Profit Margin at -207.35%, Pretax Profit Margin comes in at -171.28%, and Net Profit Margin reading is -183.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.05, Equity is -0.24 and Total Capital is -0.06. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.06.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 23.53 points at the first support level, and at 23.03 for the second support level. However, for the 1st resistance point, the stock is sitting at 24.76, and for the 2nd resistance point, it is at 25.49.
Ratios To Look Out For
For context, Zymeworks BC Inc’s Current Ratio is 6.94. In addition, the Quick Ratio stands at 6.94 and the Cash Ratio stands at 1.54. Considering the valuation of this stock, the price to sales ratio is 13.47, the price to book ratio is 5.68.
Transactions by insiders
Recent insider trading involved Neil Gallagher, Former Director, that happened on Nov 21 ’25 when 0.1 million shares were purchased. Director, EcoR1 Capital, LLC completed a deal on May 15 ’25 to buy 49502.0 shares. Meanwhile, Director EcoR1 Capital, LLC bought 5919.0 shares on May 19 ’25.
